BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 25, 2005
 |  BioCentury  |  Finance

EPS watch

EPS watch

Company 1Q05 EPS est 1Q05 EPS actual Outcome Growth from 1Q04 4/22 cls Wk chg % chg Mcap chg 4/22 Mcap
Actelion (SWX:ATLN) NA CHF1.82 NA 52% CHF 132.8 CHF 3.3 3% $61.1 $2,432.1
Tracleer bosentan to treat pulmonary arterial hypertension (PAH) posted 1Q05 sales of CHF139.8M ($117M), up 44% from CHF97.1M in 1Q04. ATLN raised its FY05 revenue guidance to CHF580-CHF600M from CHF560-CHF580M.
Affymetrix (AFFX) $0.20 $0.24 Beat by $0.04 NA $44.57 -$0.03 0% -$1.9 $2,779.0
In 1Q04, AFFX reported a loss per share of $0.03. Although the company raised its FY05 EPS guidance to $1.16 from $1.12, investors dented the stock after AFFX's 2Q05 guidance was lighter than expected. This quarter, the microarray company expects EPS of $0.16 on $87M in revenues. The Street's 2Q05 EPS and revenue estimates were $0.23 and $93.8M.
Amgen (AMGN) $0.68 $0.72 Beat by $0.04 26% $58.89 -$1.06 -2% -$1,323.9 $73,553.6
Product sales rose 24% to $2.7B in 1Q05 from $2.2B in 1Q04. Based on the strong quarter and a clearer picture of the reimbursement for its oncology drugs, AMGN raised its FY05 EPS and revenue...

Read the full 1164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >